September 01, 2026 IGC Pharma, Inc. (NYSE: IGC) is gaining attention after Ascendiant Capital Markets raised its 12-month price target to $6.00 from $5.50 while maintaining its BUY rating, citing continued clinical progress and the Company’s expanding AI-enabled Alzheimer’s programs.
The key near-term catalyst is IGC-AD1, IGC’s lead investigational therapy for agitation associated with Alzheimer’s dementia. The Phase 2 CALMA trial reached its original 146-patient randomization target and subsequently advanced to within six additional randomizations of expected enrollment closure, with topline results anticipated in Q4 2026.
Ascendiant highlighted previously reported interim CALMA results showing a clinically and statistically significant reduction in agitation compared with placebo and said additional positive data and development progress could serve as catalysts for IGC shares. IGC-AD1 is part of a broader pipeline of five Alzheimer’s therapeutic candidates, including TGR-63.
IGC is also developing AI-enabled technologies for Alzheimer’s research and drug development, with Ascendiant identifying the Company’s AI beta program as another important milestone. The research firm said it continues to view IGC’s valuation as attractive relative to its potential opportunity, raising its 12-month target to $6.00 based on a net present value analysis while acknowledging the risks inherent in clinical-stage biotechnology development.
Alongside IGC Pharma (NYSE American: IGC), investors are also watching CollPlant Biotechnologies Ltd. (NASDAQ: CLGN), Australian Oilseeds Holdings Limited (NASDAQ: COOT), VivoSim Labs, Inc. (NASDAQ: VIVS), and Ping An Biomedical Co., Ltd. (NASDAQ: PASW) as emerging-growth stocks continue attracting market attention.
With Phase 2 Alzheimer’s results expected in Q4 2026, an expanding AI program and a higher $6.00 analyst target, IGC Pharma is entering an important period that could help set the stage for its Alzheimer’s development strategy in 2027. See Entire Ascendiant Report
About IGC Pharma
IGC Pharma, Inc. (NYSE: IGC) is a clinical-stage biotechnology company developing investigational therapies for Alzheimer’s disease and AI-enabled technologies supporting drug development and clinical research. Its lead asset, IGC-AD1, is being evaluated in the Phase 2 CALMA trial for agitation associated with Alzheimer’s dementia.
About The Street Reports
The Street Reports (TSR) is a financial media awareness platform focused on emerging-growth, small-cap, micro-cap and nano-cap companies. The Street Reports publishes and distributes market-focused content across financial news, media and digital channels, providing companies with expanded visibility and exposure to a broad audience of readers and market participants.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media ContactCompany Name: The Street ReportsContact Person: EditorEmail: Send EmailCountry: United StatesWebsite: http://www.thestreetreports.com
